SRTD biotech
Key Facts
| Invested since | 2024 |
| Based in | Jülich |
About the company
SRTD biotech was founded in Jülich by Dr Bernd Hoffmann and Dr Heribert Bohlen. The aim of the biotech start-up is to develop highly efficient RNA-based drugs based on a proprietary platform technology. The team consists of experts in molecular biology, cell biology, chemistry, translational sciences and business development.
Do you want to
know more about this company?
SRTD biotech in the news
zum Artikel
SRTD biotech secures seed financing: Side-effect freeRNA therapeutics active only in diseased cells
More startups from Life Sciences
faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The …
to faCellitate
Intelligent fluids GmbH is designing innovative high performance cleaning fluids for industrial application that are unique in the world. These intelligent fluids® are based on a groundbreaking, patented technology that …
to intelligent fluids
Umlaut.bio GmbH develops small molecules that are intended to be used as first-in-class therapeutics against a variety of diseases. The focus is on the “umlauts” of the genetic code – …
to Umlaut.bio
Sedivention is developing a medical device for a new therapy of obesity. The Blizzard cryocatheter freezes the nerve branches, that transmit an increased, inadequate feeling of hunger to the brain …
to Sedivention
Exit
Sierra Sensors is combining state of the art label-free detection with cutting edge microfluidic sample delivery, sensor design, and automation, to supply researchers with high performance analytical biosensors.
to Sierra Sensors
Exit
Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic …
to Amal Therapeutics
Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays. SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in …
to Signatope
Exit
Amedrix develops & produces three dimensional implants (gel and liquid) based on collagen. Focus: treatment of articular cartilage damage in human an horse and other promising application areas. CE-mark for …
to Amedrix
Resolve Biosciences is creating solutions which offer the power of Molecular Cartography enabling scientists to gain valuable insights at subcellular resolution, across vast numbers of biomolecules (RNA, DNA, proteins) to …
to Resolve Biosciences
Exit
Vector-based technologies for cell and gene therapy applications and vaccines
to SIRION Biotech
Exit
GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with …
to GQ Bio Therapeutics
Coramaze Technologies develops an innovative, highly differentiated, transcatheter tricuspid valve repair system, called TriPair. Headquartered in Germany with an R&D hub in Israel, we promote health equity by offering a …
to coramaze